{Reference Type}: Journal Article
{Title}: Direct to Consumer Biomarker Testing for Alzheimer Disease-Are We Ready for the Insurance Consequences?
{Author}: Arias JJ;Manchester M;Lah J;
{Journal}: JAMA Neurol
{Volume}: 81
{Issue}: 2
{Year}: 2024 Feb 1
{Factor}: 29.907
{DOI}: 10.1001/jamaneurol.2023.4811
{Abstract}: This Viewpoint discusses direct-to-consumer biomarker tests for Alzheimer disease and their implications on future insurance coverage.